Skip to content
Sign in

EW · NYSE

Edwards Lifesciences (EW) Stock Price & Fundamentals

$667.66+0.69%+$4.58End-of-day price as of Oct 9, 2026

Edwards Lifesciences (EW) closed at $667.66 on Oct 9, 2026, up 0.69% from the previous close of $663.08.

Share price, past year

1Y +32.24%

52-week range $504.87 – $677.05. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$667.66
Sep 30, 2026$672.00
Aug 31, 2026$644.26
Jul 31, 2026$608.81
Jun 30, 2026$648.37
May 29, 2026$641.58
Apr 30, 2026$606.24
Mar 31, 2026$592.68
Feb 27, 2026$561.45
Jan 30, 2026$563.11
Dec 31, 2025$580.26
Nov 28, 2025$548.23
Oct 31, 2025$534.63

Key statistics

Market cap
$384.97B
P/E (TTM)
312.0
EPS (TTM)
$2.14
Revenue (TTM)
$6.51B
Net income (TTM)
$1.00B
Shares outstanding
576.6M
Dividend yield
—
52-week range
$504.87 – $677.05

Edwards Lifesciences's market cap is $384.97B, based on a share price of $667.66 and 576.6M shares outstanding as of Jun 30, 2026.

Financials

Edwards Lifesciences reported revenue of $6.07B for fiscal 2025, up 11.55% from fiscal 2024.

Edwards Lifesciences earned net income of $1.07B in fiscal 2025, a net margin of 17.7%.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Edwards Lifesciences annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$6.07B+11.6%$1.07B17.7%$1.83$1.34B
FY2024ended Dec 31, 2024$5.44B+8.6%$4.17B76.8%$6.97$289.90M
FY2023ended Dec 31, 2023$5.01B+12.2%$1.40B28.0%$2.30$642.80M
FY2022ended Dec 31, 2022$4.46B−14.7%$1.52B34.1%$2.44$973.60M
FY2021ended Dec 31, 2021$5.23B+19.3%$1.50B28.7%$2.38$1.41B
FY2020ended Dec 31, 2020$4.39B+0.9%——$1.30$647.30M
FY2019ended Dec 31, 2019$4.35B+16.8%——$1.64$928.50M
FY2018ended Dec 31, 2018$3.72B+8.4%——$1.13$688.00M
FY2017ended Dec 31, 2017$3.44B+15.9%——$0.90$832.60M
FY2016ended Dec 31, 2016$2.96B———$0.87$528.30M
Edwards Lifesciences quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$1.74B$241.90M$0.42
Q1 FY2026ended Mar 31, 2026$1.65B$380.70M$0.66
Q4 FY2025ended Dec 31, 2025$1.57B$91.20M—
Q3 FY2025ended Sep 30, 2025$1.55B$291.10M$0.50
Q2 FY2025ended Jun 30, 2025$1.53B$333.20M$0.56
Q1 FY2025ended Mar 31, 2025$1.41B$358.00M$0.61
Q4 FY2024ended Dec 31, 2024$1.39B$385.60M$0.65
Q3 FY2024ended Sep 30, 2024$1.35B$3.07B$5.13

Company profile

Name
Edwards Lifesciences Corp
Ticker
EW
Exchange
NYSE
Industry (SEC SIC)
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Headquarters
One Edwards Way, Irvine, CA 92614
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001099800

Recent SEC filings

Frequently asked questions

What is Edwards Lifesciences's stock price?

Edwards Lifesciences (EW) closed at $667.66 on Oct 9, 2026, up 0.69% from the previous close of $663.08.

What is Edwards Lifesciences's market cap?

Edwards Lifesciences's market cap is $384.97B, based on a share price of $667.66 and 576.6M shares outstanding as of Jun 30, 2026.

How much revenue does Edwards Lifesciences make?

Edwards Lifesciences reported revenue of $6.07B for fiscal 2025, up 11.55% from fiscal 2024.

What is EW's P/E ratio?

Edwards Lifesciences's price-to-earnings ratio is 312.0, based on trailing twelve-month diluted EPS of $2.14.

Does Edwards Lifesciences pay a dividend?

Edwards Lifesciences's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Edwards Lifesciences Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures